ATTACHMENT A.3_COSMOS Milestone and Payment Table.xlsx

XLSX spreadsheet 22 KB Posted

Attached to
ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening
Solicitation number
ARPA-H-SOL-26-165
Issued by

About this file

This file is a milestone and payment table template for the ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. The document outlines mandatory deliverables and milestones organized by phase and task structure, with required submissions organized by month and quarter. Key Phase 1 deliverables include material transfer agreements with commercial service flight and hardware providers (Month 2, Q1); a commercialization plan describing how tissue aging rates in space (TARIS) exceeding tissue aging rates on Earth (TAROE) could be commercialized (Month 3, Q1); a collaboration plan and timeline with CSP-Technical teams (Month 5, Q2); and a Data Management and Sharing Plan revision if needed (Month 1, Q1). Additional Phase 1 requirements include quantification of tissue aging rates using microphysiological systems (MPSs) for target organs, development of licensable datasets combining terrestrial and Low Earth Orbit (LEO) twin data, commercial CSP hardware integration plans, and final TARIS:TAROE models.

By the end of Phase 1, teams must establish signed contractual partnerships and licensing agreements with at least one commercial pharmaceutical discovery or manufacturing partner with drugs applicable to the organ type showing the greatest TARIS:TAROE differential. Phase 2 deliverables include disease model development and scaling plans, credible and reproducible disease models using microgravity-leveraged MPS technology for novel drug screening, proof-of-concept high-throughput drug testing demonstrating identification of drugs that prevent or reverse age-related tissue dysfunction, Phase 2 commercial partnership plans, and TARIS-TAROE models tables. The document serves as a structured template for proposers to populate with specific task titles, milestone descriptions, quantitative metrics, and cost allocations across the defined start and end quarters for each phase.

View the file

Other files

Show all 11

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Mandatory Deliverables

ItemMonth DueQ dueDescription
Material Transfer agreement with Commercial Service Flight provider21
Material Transfer agreement with Commercial Service Hardware provider21
Commercializaion Plan31Teams must submit a high-level commercialization plan describing how an MPS age bracket which exhibits a tissue aging rate in space (TARIS) is greater than a tissue aging rate on earth (TAROE) could be commercialized.
Collaboration plan and timeline CSP-Technical teams52
Data Management and Sharing Plan Revision (if needed)11
Quantification of Tissue Aging Rate in Space (TARIS) using microphysiological systems (MPSs) (and potentially organoids as well) for target organ
Licensable data set comprising the Terrestrial Arm data and LEO Twin Data
Commercial CSP Hardware integration plan with MPSs for timely spaceflight
Final TARIS:TAROE model of tissue changes in LEO
Signed, contractual partnership and licensing agreement with AT LEAST one commercial pharmaceutical discovery/ manufacturing partner that has drugs of interest that are applicable to the organ type with the greatest TARIS:TAROE
By the end of phase 1, each team must have a signed, contractual partnership and licensing agreement with AT LEAST one commercial pharmaceutical discovery/manufacturing partner that has drugs of interest that are applicable to the accelerated organ type
Phase II Disease Model and Scaling PlanCredible and reproducible plan to develop relevant disease model(s) within the selected organ based on state of the art,
· Credible, reproducible disease model(s) of tissues where TARIS > TAROE from Phase I successfully used in coordination with commercial partner(s) for novel drug screening
· Demonstration of proof-of-concept high throughput drug testing using microgravity-leveraged MPS models of aging to identify drugs that can prevent and/or reverse age-related tissue dysfunction and/or disease
Commercial CSP Hardware integration with MPSs for timely spaceflight
Phase II Commercial Partenrship Plan
TARIS-TAROE Models

Table

PhaseCategoryTask #Milestone #Task/Milestone TitleMilestone Description and MetricsStart QrtEnd QrtCost
Phase 1Task 1-Task Title
(include the PI and organization performing the work in parantheses)Task Description: Include a brief description of the proposed work.
Phase 1Task 1M1.1Milestone Title
(include the PI and organization performing the work in parantheses)Milestone Description: Include a brief description of the proposed work.

Quantitative Metrics: Provide a list of deliverables and quantitative exit criteria to evaluate the proposed work included in the milestone description.

Phase 1Task 1M1.2Milestone Title
(include the PI and organization performing the work in parantheses)Milestone Description: Include a brief description of the proposed work.

Quantitative Metrics: Provide a list of deliverables and quantitative exit criteria to evaluate the proposed work included in the milestone description.

Phase 1Task 1M1.3Milestone Title
(include the PI and organization performing the work in parantheses)Milestone Description: Include a brief description of the proposed work.

Quantitative Metrics: Provide a list of deliverables and quantitative exit criteria to evaluate the proposed work included in the milestone description.

Phase 1Task 2--
Phase 1Task 2M2.1
Phase 1Task 2M2.2
Phase 1Task 2M2.3
Phase 1
Phase 1Task 3-
Phase 1Task 3M3.1
Phase 1Task 3M3.2
Phase 1Task 3
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2

File details come from the government source that posted it. Updated .